Insulet (PODD) risk factors: FY2025 10-K

1. We currently rely on sales of our Omnipod product platform to generate most of our revenue.reworded
2. Our ability to grow our revenue depends in part on our retaining a high percentage of our customers.
3. If we do not effectively manage our rapid growth, our business resources may become strained and we may not be able to deliver our products in a timely manner, which could adversely affect our results of operations.
4. Failure to secure or retain adequate coverage or reimbursement for our products by third-party payors could adversely affect our business, revenue, financial condition, and results of operations.reworded
5. If we fail to expand our relationships with intermediaries, our ability to grow our business may be materially and adversely affected.new
6. Our non-insulin Drug Delivery product line faces challenges which, if not met, may impair its future success.

Read these in Item 1A · See the changes

1. Our failure to compete effectively would negatively impact our revenue and results of operations.reworded
2. Our new product development initiatives may prove to be ineffective or not commercially successful.
3. Technological breakthroughs in diabetes monitoring, treatment, or prevention could render our Omnipod products obsolete or less desirable.
4. Future market or clinical studies may be unfavorable to our Omnipod products and their efficacy, which could hinder our sales efforts and have a material adverse effect on our business, results of operations, financial condition, and cash flows.

Read these in Item 1A · See the changes

1. We may be unable to adequately protect our intellectual property rights, which could limit our ability to sell our products profitably, or at all, and cause us to incur additional costs.new
2. Claims that our current or future products infringe or misappropriate the proprietary rights of others could adversely affect our ability to sell those products and cause us to incur additional costs.

Read these in Item 1A · See the changes

1. The continuing worldwide macroeconomic and geopolitical uncertainty as well as the impact of another global pandemic may adversely affect our business and prospects.reworded
2. The international nature of our business subjects us to additional business risks that may have an adverse effect on our financial condition or results of operations.new
3. Expansion of U.S. tariffs could have a material adverse effect on our financial results.newTariffs

Read these in Item 1A · See the changes

1. We rely on agreements or licenses to intellectual property or other rights in order to sell our current product and commercialize new products.
2. Our inventory is produced and maintained in a limited number of locations, including one operated by a third party in China, and any loss could have a material adverse effect on our ability to manufacture and sell our products.newChina
3. We are dependent upon third-party suppliers, making us vulnerable to supply constraints and price fluctuations, and we may not be able to obtain sufficient components or raw materials on a timely basis or at all.reworded
4. Our manufacturing process is highly complex and subject to regulation; as demand for our products increase, we may experience manufacturing difficulties, including not effectively managing the start-up of new manufacturing lines or issues with our third-party contract manufacturer, which could harm our business.
5. If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval or commercialize our products.

Read these in Item 1A · See the changes

1. Healthcare reform laws could adversely affect our revenue and financial condition.
2. We are subject to extensive government regulation, which could restrict the sales and marketing of our products, cause us to incur significant costs, and impact our profitability and competitiveness.reworded
3. If we or our contract manufacturer fail to comply with the FDA’s quality system regulations, the manufacturing and distribution of our devices could be interrupted, and our sales and operating results could suffer.reworded
4. Malfunction of our products could lead to recalls, safety alerts, or litigation and result in substantial costs and reputational damage.new
5. We may be subject to enforcement action if we engage in improper marketing or promotion of our products.
6. If we fail to comply with fraud and abuse and other healthcare regulations, including those relating to Medicare and Medicaid, we could be subject to substantial penalties and/or be excluded from participation in government programs.reworded
7. Failure to comply with the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws could materially adversely affect our business and result in civil and/or criminal sanctions.

Read these in Item 1A · See the changes

1. We are subject to complex and evolving laws and regulations regarding privacy, data protection, and artificial intelligence (“AI”), many of which are subject to change and uncertain interpretation, which could result in legal claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement.rewordedAI
2. We rely on the proper function, availability, and security of our products and IT systems; a successful cyber-attack or other breach or disruption of our products or these systems could have a material adverse effect on our business and results of operations.rewordedCybersecurity
3. Failure to maintain the privacy and security of our customer, third-party payor, employee, supplier, or Company information could result in substantial costs and/or subject us to litigation, enforcement actions, and reputational damage.

Read these in Item 1A · See the changes

1. Our Credit Agreement imposes restrictions on us that may adversely affect our ability to operate or grow our business.reworded
2. We may need to raise additional funds in the future, and these funds may not be available on acceptable terms or at all.

Read these in Item 1A · See the changes

1. Our success depends on our ability to attract, motivate, and retain key personnel.
2. Acquisitions or investments in new businesses, products, or technologies could disrupt our business.
3. The price of our common stock may be volatile.
4. Changes in tax laws or exposures to additional tax liabilities could negatively impact our operating results.

Read these in Item 1A · See the changes

Headings in the FY2024 10-K with no match this year.

1. If we fail to expand and maintain an effective sales force or successfully develop and maintain our relationships with intermediaries, our business, prospects, and brand may be materially and adversely affected.
2. We may be unable to adequately protect our intellectual property rights.
3. Another global pandemic could adversely impact our business and financial condition.
4. Our financial condition or results of operations may be adversely affected by international business risks.
5. Our inventory is produced and maintained in a limited number of locations.
6. Malfunction of our products could lead to recalls or safety alerts or litigation and have a significant adverse impact on us.
7. The rapidly-changing technical and regulatory environment and our AI-related activities may have an adverse effect on our business.
8. Conversion of any of our Convertible Senior Notes may dilute the ownership interest of existing stockholders or depress our stock price.
9. A material weakness in our internal control over financial reporting could result in material misstatements in our financial statements and cause us to fail to meet our reporting and financial obligations.